drugset / Trial / NCT01722604

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

NCT01722604

Phase 3 Completed 258 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupDouble-blindHealth-services research

Summary

The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic suspension 1%) dosed three times daily in IOP reduction in patients with POAG or OH.

Timeline

Start
2012-01
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Brinzolamide Small molecule 1 % Topical

Indications